Related references
Note: Only part of the references are listed.Cyclotherapy: opening a therapeutic window in cancer treatment
Ingeborg M.M. van Leeuwen
Oncotarget (2015)
Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity
Toru Okamoto et al.
ACS CHEMICAL BIOLOGY (2013)
Stapled Peptides with Improved Potency and Specificity That Activate p53
Christopher J. Brown et al.
ACS CHEMICAL BIOLOGY (2013)
Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach
Mariana Leao et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors
Taro Noguchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Prognostic impact and targeting of CRM1 in acute myeloid leukemia
Kensuke Kojima et al.
BLOOD (2013)
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Hege O. Ohnstad et al.
CANCER (2013)
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP
Min Lu et al.
CANCER CELL (2013)
Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924
Jonathan L. Blank et al.
CANCER RESEARCH (2013)
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Christian Tovar et al.
CANCER RESEARCH (2013)
Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4
Matthias Gutekunst et al.
CANCER RESEARCH (2013)
Non-Cell-Autonomous Tumor Suppression by p53
Amaia Lujambio et al.
CELL (2013)
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins
Karim M. ElSawy et al.
CELL CYCLE (2013)
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest
Changyou Li et al.
CELL CYCLE (2013)
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
M. Kracikova et al.
CELL DEATH AND DIFFERENTIATION (2013)
Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells
Roser Mir et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Rational Design and Binding Mode Duality of MDM2-p53 Inhibitors
Felix Gonzalez-Lopez de Turiso et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
Alessia Bertamino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide
Yanbin Ji et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Association of the miR-146aC>G, miR-149T>C, miR-196a2T>C, and miR-499A>G Polymorphisms With Gastric Cancer Risk and Survival in the Korean Population
Dae Ho Ahn et al.
MOLECULAR CARCINOGENESIS (2013)
Small molecule induced reactivation of mutant p53 in cancer cells
Xiangrui Liu et al.
NUCLEIC ACIDS RESEARCH (2013)
Siladenoserinols A-L: New Sulfonated Serinol Derivatives from a Tunicate as Inhibitors of p53-Hdm2 Interaction
Yuichi Nakamura et al.
ORGANIC LETTERS (2013)
In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Siau Jia Wei et al.
PLOS ONE (2013)
Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides
Siau Jia Wei et al.
PLOS ONE (2013)
Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET
Ruby Shalom-Feuerstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations
Jinfeng Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
Yong S. Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Ksenya Shchors et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry
Lenka Hernychova et al.
PROTEOMICS (2013)
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina et al.
SCIENCE (2013)
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Binh Vu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Christopher D. Wassman et al.
NATURE COMMUNICATIONS (2013)
p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo
Oleg Timofeev et al.
CELL REPORTS (2013)
p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa
Liz J. Valente et al.
CELL REPORTS (2013)
Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation
Teng Ma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Structural insights into the dual-targeting mechanism of Nutlin-3
Jae-Sun Shin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S. Davids et al.
BLOOD (2012)
Translational approaches targeting the p53 pathway for anti-cancer therapy
Frank Essmann et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
Ling Li et al.
CANCER CELL (2012)
ATM Phosphorylation of Mdm2 Ser394 Regulates the Amplitude and Duration of the DNA Damage Response in Mice
Hugh S. Gannon et al.
CANCER CELL (2012)
p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
James G. Jackson et al.
CANCER CELL (2012)
Small molecules that bind the Mdm2 RING stabilize and activate p53
Patricia Roxburgh et al.
CARCINOGENESIS (2012)
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Tongyuan Li et al.
CELL (2012)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo et al.
CELL (2012)
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
Ingeborg M. M. van Leeuwen et al.
CELL CYCLE (2012)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX
Ryan E. Henry et al.
EMBO JOURNAL (2012)
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils
Alexander H. Stegh
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Stefan P. Glaser et al.
GENES & DEVELOPMENT (2012)
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status
Giorgio Zauli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy
Refik Kayali et al.
HUMAN MOLECULAR GENETICS (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Structure-Based Design of Novel Inhibitors of the MDM2-p53 Interaction
Yosup Rew et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
An Expeditious Synthesis of the MDM2-p53 Inhibitor AM-8553
Brian S. Lucas et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors
Klaus Michelsen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53
Rainer Wilcken et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Richard J. Jones et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells
Marc J. Rigatti et al.
MOLECULAR CARCINOGENESIS (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
M. Konopleva et al.
LEUKEMIA (2012)
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
E. McCormack et al.
LEUKEMIA (2012)
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Kelly D. Sullivan et al.
NATURE CHEMICAL BIOLOGY (2012)
MDM4 is a key therapeutic target in cutaneous melanoma
Agnieszka Gembarska et al.
NATURE MEDICINE (2012)
Improved eIF4E Binding Peptides by Phage Display Guided Design: Plasticity of Interacting Surfaces Yield Collective Effects
Weizhuang Zhou et al.
PLOS ONE (2012)
A Spiroligomer α-Helix Mimic That Binds HDM2, Penetrates Human Cells and Stabilizes HDM2 in Cell Culture
Zachary Z. Brown et al.
PLOS ONE (2012)
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Bradford Graves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
R. W. Rooswinkel et al.
CELL DEATH & DISEASE (2012)
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Jane M. Valentine et al.
BMC CANCER (2011)
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Colleen A. Brady et al.
CELL (2011)
NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anti-cancer compounds
Qiao Jing Lew et al.
CELL CYCLE (2011)
Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
Rosa Puca et al.
CELL CYCLE (2011)
Mechanism-specific signatures for small-molecule p53 activators
Ingeborg M. M. van Leeuwen et al.
CELL CYCLE (2011)
Understanding Small-Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy
Christiane Riedinger et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
Giorgio Zauli et al.
CLINICAL CANCER RESEARCH (2011)
iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe
LiLi Jiang et al.
CLINICAL CANCER RESEARCH (2011)
PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
Roza Zandi et al.
CLINICAL CANCER RESEARCH (2011)
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
Daniel Garcia et al.
GENES & DEVELOPMENT (2011)
Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency
Ian R. Hardcastle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Identification of Two Reactive Cysteine Residues in the Tumor Suppressor Protein p53 Using Top-Down FTICR Mass Spectrometry
Jenna Scotcher et al.
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2011)
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer
Christian Tovar et al.
MOLECULAR CANCER (2011)
Translating p53 into the clinic
Chit Fang Cheok et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
Celia Floquet et al.
NUCLEIC ACIDS RESEARCH (2011)
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
A. S. Azmi et al.
ONCOGENE (2011)
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
M. H. Aziz et al.
ONCOGENE (2011)
p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin
Matthias Gutekunst et al.
PLOS ONE (2011)
C-Terminal Substitution of MDM2 Interacting Peptides Modulates Binding Affinity by Distinctive Mechanisms
Christopher J. Brown et al.
PLOS ONE (2011)
Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages
Dadi Jiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Lei Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
M. Michaelis et al.
CELL DEATH & DISEASE (2011)
Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
Isabelle Sermet-Gaudelus et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists
Anna Czarna et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
DNA damage response to the Mdm2 inhibitor Nutlin-3
Rajeev Verma et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML
Bing Z. Carter et al.
BLOOD (2010)
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim
Lina Happo et al.
BLOOD (2010)
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies et al.
BLOOD (2010)
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
Jianting Long et al.
BLOOD (2010)
Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma Evidence for p53-transcription-dependent and -independent pathways
Manujendra N. Saha et al.
CANCER BIOLOGY & THERAPY (2010)
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Federico Bernal et al.
CANCER CELL (2010)
Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim
Weiguo Zhang et al.
CANCER RESEARCH (2010)
Life or death p53-induced apoptosis requires DNA binding cooperativity
Katharina Schlereth et al.
CELL CYCLE (2010)
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
C. F. Cheok et al.
CELL DEATH AND DIFFERENTIATION (2010)
Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant
Nicolas Basse et al.
CHEMISTRY & BIOLOGY (2010)
Regulation of the p53 pathway by ubiquitin and related proteins
Andreas Hock et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX
Jason Phan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Damon Reed et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Systematic Mutational Analysis of Peptide Inhibition of the p53-MDM2/MDMX Interactions
Chong Li et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Targeted Quantitation of Site-Specific Cysteine Oxidation in Endogenous Proteins Using a Differential Alkylation and Multiple Reaction Monitoring Mass Spectrometry Approach
Jason M. Held et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53
Thelma Thompson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Katharina Schlereth et al.
MOLECULAR CELL (2010)
The missing Zinc: p53 misfolding and cancer
Stewart N. Loh
METALLOMICS (2010)
PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
N. Rokaeus et al.
ONCOGENE (2010)
Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells
R. Puca et al.
ONCOGENE (2010)
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms
Min Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124
Douglas S. Auld et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding
Joel L. Kaar et al.
PROTEIN SCIENCE (2010)
Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases Progress in Development
Steven M. Rowe et al.
BIODRUGS (2009)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Martin Michaelis et al.
CANCER RESEARCH (2009)
Modes of p53 Regulation
Jan-Philipp Kruse et al.
CELL (2009)
Specific activation of the p53 pathway by low dose actinomycin D A new route to p53 based cyclotherapy
Meng Ling Choong et al.
CELL CYCLE (2009)
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Yoko Tabe et al.
CLINICAL CANCER RESEARCH (2009)
Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction
John G. Allen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Adaptive Evolution of p53 Thermodynamic Stability
Kian Hoe Khoo et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
Tom Van Maerken et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?
Mark Wade et al.
MOLECULAR CANCER RESEARCH (2009)
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
Colin J. D. Ross et al.
NATURE GENETICS (2009)
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
Surojit Sur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression
Douglas S. Auld et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Marzena Pazgiera et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
Structural biology of the tumor suppressor p53
Andreas C. Joerger et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
Kensuke Kojima et al.
BLOOD (2008)
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator
Sonia Lain et al.
CANCER CELL (2008)
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Mark Wade et al.
CELL CYCLE (2008)
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
Ramiro Paris et al.
CELL CYCLE (2008)
In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute
E. M. Michalak et al.
CELL DEATH AND DIFFERENTIATION (2008)
Multiple peptide conformations give rise to similar binding affinities: Molecular simulations of p53-MDM2
Shubhra Ghosh Dastidar et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Eitan Kerem et al.
LANCET (2008)
Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
Jirouta Kitagaki et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
Stephane Supiot et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Modelling Myc inhibition as a cancer therapy
Laura Soucek et al.
NATURE (2008)
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA
Dmitry B. Veprintsev et al.
NUCLEIC ACIDS RESEARCH (2008)
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Sanjeev Shangary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Introducing sense into nonsense in treatments of human genetic diseases
Liat Linde et al.
TRENDS IN GENETICS (2008)
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination
Chit Fang Cheok et al.
MOLECULAR CANCER RESEARCH (2007)
The MDM-2 antagonist Nutlin-3 promotes the maturation of acute myeloid leukemic blasts
Paola Secchiero et al.
NEOPLASIA (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A. C. Joerger et al.
ONCOGENE (2007)
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells
Kensuke Kojima et al.
CANCER RESEARCH (2007)
Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
Federico Bernal et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells
Brian D. Lehmann et al.
CELL CYCLE (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Modeling the therapeutic efficacy of p53 restoration in tumors
Carla P. Martins et al.
CELL (2006)
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ingo Ringshausen et al.
CANCER CELL (2006)
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML
Kensuke Kojima et al.
CELL CYCLE (2006)
Hdmx modulates the outcome of P53 activation in human tumor cells
Mark Wade et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy
Dominique Kranz et al.
CANCER RESEARCH (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
A stapled BID BH3 helix directly binds and activates BAX
Loren D. Walensky et al.
MOLECULAR CELL (2006)
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53
Daniele Bergamaschi et al.
NATURE GENETICS (2006)
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
M. A. Christophorou et al.
NATURE (2006)
Policing of oncogene activity by p53
Alejo Efeyan et al.
NATURE (2006)
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastorna cells to nutlin-3-induced apoptosis
Judit Ribas et al.
EXPERIMENTAL CELL RESEARCH (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
Llorenc Coll-Mulet et al.
BLOOD (2006)
Tumor suppression by p53 without accelerated aging - Just enough of a good thing?
Susan M. Mendrysa et al.
CELL CYCLE (2006)
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
TR Brummelkamp et al.
NATURE CHEMICAL BIOLOGY (2006)
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3
JT Patton et al.
CANCER RESEARCH (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
C Cao et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Benzodiazepinedione inhibitors of the Hdm2 : p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
HK Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The antioxidant function of the p53 tumor suppressor
AA Sablina et al.
NATURE MEDICINE (2005)
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles
AR Sawkar et al.
CHEMISTRY & BIOLOGY (2005)
Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
DE MacCallum et al.
CANCER RESEARCH (2005)
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors
D Carvajal et al.
CANCER RESEARCH (2005)
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
BL Grasberger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
The expression of iASPP in acute leukemias
XW Zhang et al.
LEUKEMIA RESEARCH (2005)
Chalcones: An update on cytotoxic and chemoprotective properties
ML Go et al.
CURRENT MEDICINAL CHEMISTRY (2005)
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction
H Yin et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis
JE Chipuk et al.
SCIENCE (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix
LD Walensky et al.
SCIENCE (2004)
A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells
PS Galatin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
TNF-related apoptosis-inducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies
P Secchiero et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
p53 has a direct apoptogenic role at the mitochondria
M Mihara et al.
MOLECULAR CELL (2003)
mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation
SM Mendrysa et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Acetylation of p53 inhibits its ubiquitination by Mdm2
MY Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Chemical chaperones increase the cellular activity of N370S β-glucosidase:: A therapeutic strategy for Gaucher disease
AR Sawkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally
I García-Cao et al.
EMBO JOURNAL (2002)
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins
M Konopleva et al.
LEUKEMIA (2002)
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2
TG Hofmann et al.
NATURE CELL BIOLOGY (2002)
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
G D'Orazi et al.
NATURE CELL BIOLOGY (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
ASPP proteins specifically stimulate the apoptotic function of p53
Y Samuels-Lev et al.
MOLECULAR CELL (2001)
Toward proteomimetics:: Terphenyl derivatives as structural and functional mimics of extended regions of an α-helix
BP Orner et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2001)
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
R Stoll et al.
BIOCHEMISTRY (2001)
p53AlP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
K Oda et al.
CELL (2000)
An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides
CE Schafmeister et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
P Chène et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase - Effect on Mdm2 binding
K Sakaguchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations
PV Nikolova et al.
EMBO JOURNAL (2000)
Share Paper
